News
NAVLIN DAILY
6+ hour, 46+ min ago (14+ words) TLV Introduces New Ceiling Price Regulations for Generic Medicines from October 2026 NAVLIN DAILY...
Pharmaceutical Spending in Spain Up 55% Since 2015, Regional Gaps Widen
1+ mon, 3+ week ago (65+ words) Redefining the QA Role in the Age of AI SIUU vs. Unsolicited Off'Label Requests: A Practical Comparison The Integrated Advantage: What Medical Affairs Needs Right Now Solving The Rare Disease Launch Paradox " Using Pre'Launch Planning and Partnership to Create Value…...
Google News
1+ mon, 3+ week ago (12+ words) Interpharma Warns that New U. S. Tariffs Will Impact Swiss Patients'NAVLIN DAILY...
Denmark Recommends 2 Drugs & Rejects 4
2+ mon, 4+ day ago (80+ words) Solving The Rare Disease Launch Paradox " Using Pre'Launch Planning and Partnership to Create Value EVERSANA's AI Agency Platform Wins 2026 AI Excellence Award It's Time for Commercialization to Catch Up to Innovation in Women's Health 4th Annual Brand Planning Report: Fueling Brand…...
EPA Q&A: Neil Grubert on MFN, Europe, China and What Comes Next
2+ mon, 3+ week ago (1805+ words) NAVLIN Daily (ND): Hi, Neil. I went to your talk earlier, it really was a whistle-stop tour. There has been so much going on. As you mentioned, MFN has put some companies on pause in Europe. That directly contradicts the…...
Virginia Lawmakers Replace PDAB Bill with New Legislation to Tackle Prescription Drug Prices
2+ mon, 3+ week ago (59+ words) Gartner Is Right " About the Wrong Kind of Agency AI Platform Advancing Medical Affairs Through Data and Scientific Communications: Key Takeaways from DIA MASC 2026 Scaling Practical AI Across Commercial Teams Key Implications of Recent U. S. PBM Reforms Building a scalable GLP…...
Jamaican Regulator Orders Divestment for $30 Billion+ Insulin Market
2+ mon, 3+ week ago (61+ words) Key Implications of Recent U. S. PBM Reforms Building a scalable GLP-1 care model Navigating the Intersection of AI, Global Commercialization and Patient Value Recognizing Rare Disease Day: Advancing Hope, Access and Innovation Why Our AI Agency Is So Much More Than…...
Kazakhstan Targets 38 New Meds by 2029 to Boost Domestic Drug Production
2+ mon, 3+ week ago (61+ words) Key Implications of Recent U. S. PBM Reforms Building a scalable GLP-1 care model Navigating the Intersection of AI, Global Commercialization and Patient Value Recognizing Rare Disease Day: Advancing Hope, Access and Innovation Why Our AI Agency Is So Much More Than…...
EU Pharma Reform Introduces Three-year Launch Obligation for Medicines
2+ mon, 3+ week ago (632+ words) BRUSSELS, Belgium " The EU has set out the terms of a new launch obligation for medicines, requiring pharmaceutical companies to make approved drugs available in requesting Member States within three years or risk losing regulatory market protection in that country....
EPA 2026: "MFN is the Cue Ball on a Billiards Table
2+ mon, 4+ week ago (546+ words) AMSTERDAM, The Netherlands " Most Favored Nation (MFN) is already reshaping global launch strategies; that was the central message from a pricing panel at the World Evidence, Pricing and Access (EPA) Congress in Amsterdam, where speakers warned that the policy's ripple…...